CRC
MCID: CLR023
MIFTS: 99

Colorectal Cancer (CRC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Colorectal Cancer

MalaCards integrated aliases for Colorectal Cancer:

Name: Colorectal Cancer 58 39 12 76 38 30 56 6 44 15 64 17 74
Colon Cancer 58 12 76 30 13 56 6 15
Colorectal Carcinoma 12 56 15 17 74
Colon Carcinoma 12 56 15 17 74
Colorectal Cancer, Susceptibility to 58 30 6
Carcinoma of Colon 12 30 6
Colonic Adenoma Recurrence, Reduced Risk of 58 6
Colon Cancer, Susceptibility to 58 6
Colorectal Cancer, Somatic 58 13
Colon Cancer, Somatic 58 13
Colonic Neoplasms 45 74
Crc 58 76
Colon Cancer, Advanced, Somatic 58
Cancer, Colorectal, Somatic 41
Malignant Tumor of Colon 74
Colorectal Neoplasms 74
Cancer, Colorectal 41
Colonic Carcinoma 12
Colonic Neoplasm 17
Cancer, Colon 41

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation


HPO:

33
colorectal cancer:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



Summaries for Colorectal Cancer

PubMed Health : 64 About colorectal cancer: Colorectal (bowel) cancer is one of the more common forms of cancer in many countries, including Germany. The name "colorectal cancer" is used to describe bowel cancer that starts in the colon (the large intestine) or the rectum. Cancer of the small intestine is very rare.Colorectal cancer almost always develops from growths called colorectal polyps that form in the lining of the colon. But by no means do all polyps become cancerous – and if a polyp does become cancerous, it takes many years. One way to prevent colorectal cancer is to have a colonoscopy, which also allows doctors to remove polyps.Having colorectal cancer can be a life-changing experience. What happens after the diagnosis has been made will depend on various factors, including the stage of the cancer. In early-stage colorectal cancer, the tumor just needs to be surgically removed. In advanced stages, additional treatments may be considered, such as chemotherapy or radiation therapy.In Germany, high-quality medical care is available for people who have cancer. There are also a number of sources of support, for instance to help cope with the disease emotionally and make it easier to go back to work.

MalaCards based summary : Colorectal Cancer, also known as colon cancer, is related to lynch syndrome and colorectal cancer, hereditary nonpolyposis, type 7, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Colorectal Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Colorectal cancer and MicroRNAs in cancer. The drugs Avastin and Campostar have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are renal cell carcinoma and neoplasm of the stomach

Disease Ontology : 12 A large intestine cancer that is located in the colon and/or located in the rectum.

OMIM : 58 Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and environmental risk factors, gene defects can contribute to an inherited predisposition to CRC. CRC is caused by changes in different molecular pathogenic pathways, such as chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Chromosome instability is the most common alteration and is present in almost 85% of all cases (review by Schweiger et al., 2013). (114500)

MedlinePlus : 44 The colon and rectum are part of the large intestine. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50. You're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or Crohn's disease, eat a diet high in fat, or smoke. Symptoms of colorectal cancer include Diarrhea or constipation A feeling that your bowel does not empty completely Blood (either bright red or very dark) in your stool Stools that are narrower than usual Frequent gas pains or cramps, or feeling full or bloated Weight loss with no known reason Fatigue Nausea or vomiting Because you may not have symptoms at first, it's important to have screening tests. Everyone over 50 should get screened. Tests include colonoscopy and tests for blood in the stool. Treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. Surgery can usually cure it when it is found early. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 76 Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

Wikipedia : 77 Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from... more...

Related Diseases for Colorectal Cancer

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 2
Colorectal Cancer 3 Colorectal Cancer 5
Colorectal Cancer 6 Colorectal Cancer 7
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 10 Colorectal Cancer 11
Colorectal Cancer 12 Familial Colorectal Cancer
Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 908)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 35.1 APC CTNNB1 MLH1 MLH3 TP53
2 colorectal cancer, hereditary nonpolyposis, type 7 35.1 MLH1 MLH3
3 familial colorectal cancer 35.0 APC MLH1 TP53
4 familial adenomatous polyposis 34.2 APC AXIN2 CTNNB1 MCC MLH1 TP53
5 polyposis syndrome, hereditary mixed, 1 34.0 APC MLH1
6 mismatch repair cancer syndrome 33.7 APC CTNNB1 MLH1
7 familial adenomatous polyposis 1 33.2 APC CTNNB1
8 colonic disease 33.2 AKT1 CTNNB1 MLH1 TP53
9 colon adenocarcinoma 33.1 APC BAX CTNNB1 MLH1
10 adenoma 32.9 APC AXIN2 CTNNB1 MLH1 TP53
11 adenocarcinoma 32.7 AKT1 APC CTNNB1 FGFR3 MLH1 PIK3CA
12 large intestine cancer 32.6 AKT1 APC AXIN2 CTNNB1 DCC MLH1
13 endometrial cancer 32.6 AKT1 BAX CTNNB1 MLH1 MLH3 PIK3CA
14 hepatocellular carcinoma 32.5 AKT1 APC BAX CTNNB1 DLC1 NRAS
15 gastric cancer 32.4 AKT1 APC BAX CTNNB1 MLH1 PIK3CA
16 colorectal adenoma 32.3 APC CTNNB1 MLH1 TP53
17 ovarian cancer 32.1 AKT1 BAX CTNNB1 MLH1 PIK3CA TP53
18 esophageal cancer 31.8 AKT1 BAX CTNNB1 DCC PIK3CA TP53
19 medulloblastoma 31.7 AKT1 APC CTNNB1 NRAS PIK3CA TP53
20 lung cancer susceptibility 3 31.6 AKT1 APC CTNNB1 FGFR3 NRAS PIK3CA
21 squamous cell carcinoma 31.6 AKT1 CTNNB1 FGFR3 PIK3CA TP53
22 cervical cancer 31.5 AKT1 BAX CTNNB1 FGFR3 PIK3CA TP53
23 cholangiocarcinoma 31.5 AKT1 CTNNB1 PIK3CA TP53
24 colorectal adenocarcinoma 31.5 CTNNB1 MLH1 TP53
25 adrenocortical carcinoma, hereditary 31.4 CTNNB1 NRAS PIK3CA TP53
26 desmoid disease, hereditary 31.4 APC CTNNB1
27 squamous cell carcinoma, head and neck 31.4 AKT1 CTNNB1 FGFR3 PIK3CA TP53
28 lymphoma, non-hodgkin, familial 31.4 BAX NRAS PIK3CA RAD54B TP53
29 thyroid cancer 31.3 AKT1 APC CTNNB1 NRAS PIK3CA TP53
30 gastrointestinal system disease 31.3 AKT1 CTNNB1 MLH1 TP53
31 gallbladder cancer 31.3 AKT1 MLH1 PIK3CA TP53
32 intestinal disease 31.2 AKT1 CTNNB1 MLH1 PIK3CA TP53
33 hyperplastic polyposis syndrome 31.2 APC TP53
34 peutz-jeghers syndrome 31.1 APC CTNNB1 TP53
35 endometrial adenocarcinoma 31.1 AKT1 CTNNB1 MLH1 TP53
36 breast adenocarcinoma 31.1 AKT1 BAX PIK3CA TP53
37 pancreas adenocarcinoma 31.1 AKT1 CTNNB1 PIK3CA TP53
38 serous cystadenocarcinoma 31.0 AKT1 PIK3CA TP53
39 myeloma, multiple 30.9 AKT1 FGFR3 NRAS TP53
40 suppression of tumorigenicity 12 30.9 AKT1 CTNNB1 PIK3CA TP53
41 melanoma, cutaneous malignant 1 30.9 CTNNB1 NRAS PIK3CA TP53
42 cystadenocarcinoma 30.9 AKT1 PIK3CA TP53
43 carcinosarcoma 30.8 CTNNB1 PIK3CA TP53
44 bladder disease 30.8 AKT1 FGFR3 TP53
45 ovarian cancer 1 30.8 AKT1 PIK3CA TP53
46 uterine carcinosarcoma 30.8 CTNNB1 PIK3CA TP53
47 hepatoblastoma 30.7 APC CTNNB1 TP53
48 colorectal cancer, hereditary nonpolyposis, type 5 12.7
49 colorectal cancer, hereditary nonpolyposis, type 4 12.7
50 colorectal cancer, hereditary nonpolyposis, type 8 12.7

Comorbidity relations with Colorectal Cancer via Phenotypic Disease Network (PDN): (show all 21)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Ascending Colon Cancer
Cecal Benign Neoplasm Deficiency Anemia
Descending Colon Cancer Familial Atrial Fibrillation
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Intestinal Obstruction
Intestinal Perforation Iron Deficiency Anemia
Neutropenia Paralytic Ileus
Protein-Energy Malnutrition Rectosigmoid Junction Neoplasm
Small Intestine Cancer Splenic Flexure Cancer
Transverse Colon Cancer

Graphical network of the top 20 diseases related to Colorectal Cancer:



Diseases related to Colorectal Cancer

Symptoms & Phenotypes for Colorectal Cancer

Human phenotypes related to Colorectal Cancer:

33
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 33 HP:0005584
2 neoplasm of the stomach 33 HP:0006753
3 transitional cell carcinoma of the bladder 33 HP:0006740
4 uterine leiomyosarcoma 33 HP:0002891
5 hereditary nonpolyposis colorectal carcinoma 33 HP:0006716

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
colorectal cancer

Clinical features from OMIM:

114500

UMLS symptoms related to Colorectal Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Colorectal Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.45 PIK3CA
2 Decreased viability GR00221-A-1 10.45 AKT1 FGFR3 PIK3CA NRAS PDGFRL
3 Decreased viability GR00221-A-2 10.45 AKT1 DCC EP300 FGFR3 PIK3CA
4 Decreased viability GR00221-A-3 10.45 AKT1 DCC FGFR3 NRAS
5 Decreased viability GR00221-A-4 10.45 AKT1 DCC PIK3CA
6 Decreased viability GR00402-S-2 10.45 AKT1 DCC EP300 FGFR3 PIK3CA NRAS
7 Decreased ionizing radiation sensitivity GR00232-A-1 9.86 AKT1 AXIN2 EP300 MLH1 NRAS PTPN12
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 AKT1 BAX DCC MLH1 PDGFRL RAD54B
9 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 AKT1 BAX DCC MLH1 PDGFRL RAD54B
10 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 BAX EP300 MLH1 MLH3 RAD54B TP53

MGI Mouse Phenotypes related to Colorectal Cancer:

47 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 AKT1 APC AXIN2 BAX CTNNB1 DCC
2 hematopoietic system MP:0005397 10.45 AKT1 APC BAX CTNNB1 DCC DLC1
3 mortality/aging MP:0010768 10.44 AKT1 APC AXIN2 BAX CTNNB1 DCC
4 growth/size/body region MP:0005378 10.43 AKT1 APC AXIN2 BAX CTNNB1 DLC1
5 homeostasis/metabolism MP:0005376 10.41 AKT1 APC BAX CTNNB1 DLC1 EP300
6 cardiovascular system MP:0005385 10.4 AKT1 APC AXIN2 CTNNB1 DLC1 EP300
7 immune system MP:0005387 10.4 AKT1 APC BAX CTNNB1 DCC EP300
8 embryo MP:0005380 10.38 AKT1 APC AXIN2 CTNNB1 DLC1 EP300
9 endocrine/exocrine gland MP:0005379 10.33 AKT1 APC AXIN2 BAX CTNNB1 EP300
10 neoplasm MP:0002006 10.29 AKT1 APC BAX CTNNB1 DCC EP300
11 nervous system MP:0003631 10.23 AKT1 APC AXIN2 BAX CTNNB1 DCC
12 craniofacial MP:0005382 10.21 APC AXIN2 CTNNB1 DLC1 EP300 FGFR3
13 digestive/alimentary MP:0005381 10.21 APC CTNNB1 DCC EP300 FGFR3 MLH1
14 integument MP:0010771 10.15 AKT1 APC CTNNB1 FGFR3 MLH1 NRAS
15 normal MP:0002873 10.14 AKT1 APC AXIN2 CTNNB1 DLC1 EP300
16 muscle MP:0005369 10.1 AKT1 APC BAX CTNNB1 EP300 PIK3CA
17 limbs/digits/tail MP:0005371 10.08 APC AXIN2 BAX CTNNB1 FGFR3 NRAS
18 liver/biliary system MP:0005370 10.07 AKT1 APC CTNNB1 NRAS PTPN12 PTPRJ
19 no phenotypic analysis MP:0003012 10.03 AXIN2 CTNNB1 FGFR3 NRAS PIK3CA PTPN12
20 reproductive system MP:0005389 10 AKT1 APC AXIN2 BAX CTNNB1 FGFR3
21 renal/urinary system MP:0005367 9.87 APC BAX CTNNB1 EP300 FGFR3 FLCN
22 respiratory system MP:0005388 9.81 AKT1 BAX CTNNB1 DCC EP300 FGFR3
23 pigmentation MP:0001186 9.77 APC CTNNB1 DCC NRAS TP53
24 skeleton MP:0005390 9.61 AKT1 APC AXIN2 BAX CTNNB1 FGFR3
25 vision/eye MP:0005391 9.36 APC AXIN2 BAX CTNNB1 DCC EP300

Drugs & Therapeutics for Colorectal Cancer

PubMedHealth treatment related to Colorectal Cancer: 64

Surgery is performed to remove as much of the cancer as possible. In early stages, further treatment may not be needed. If the cancer is at a more advanced stage, further treatments like radiation therapy or chemotherapy are options.

FDA approved drugs:

(show all 13)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Avastin 19 50 BEVACIZUMAB Genentech July 2009
2
Campostar 19 50 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
3
CEA-Scan 19 Immunomedics April 1996
4
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
5
Eloxatin 19 50 OXALIPLATIN Sanofi-aventis August 2002
6
Erbitux 19 50 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
7
Fusilev 19 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
8
Iressa 19 50 GEFITINIB AstraZeneca May 2003
9
Stivarga 19 50 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
10
Sutent 19 50 SUNITINIB MALATE Pfizer May 2011/ January 2006
11
Vectibix 19 50 PANITUMUMAB Amgen September 2006
12
Xeloda 19 50 CAPECITABINE Roche April 1998/ May 2001
13
Zaltrap 19 50 ZIV-AFLIBERCEPT Sanofi-aventis August 2012

Drugs for Colorectal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1023)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 17902-23-7 5386
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
4
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112887-68-0 104758
5
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
6 Ethiodized oil Approved, Investigational Phase 4,Phase 2 8008-53-5
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
8
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
9
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
10
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
11
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
12
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
13
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7553-56-2 807
14
Phylloquinone Approved, Investigational Phase 4,Phase 2,Phase 1 84-80-0
15 Menaquinone Approved, Investigational Phase 4,Phase 2,Phase 1 1182-68-9
16
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
17
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 137-58-6 3676
18
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
19
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 114-07-8 441411 12560
20
Bisacodyl Approved Phase 4,Phase 3,Not Applicable 603-50-9
21
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38396-39-3, 2180-92-9 2474
22
Ketorolac Approved Phase 4,Phase 2,Not Applicable 74103-06-3, 66635-83-4 3826
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 437-38-7 3345
24
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
25
Acetaminophen Approved Phase 4,Phase 2,Not Applicable 103-90-2 1983
26
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 1,Not Applicable 76-42-6 5284603
27
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
28
Methadone Approved, Illicit Phase 4,Phase 1,Phase 2 76-99-3 4095
29
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
30
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
31
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 93-14-1 3516
32
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
33
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
34
Orphenadrine Approved Phase 4 83-98-7 4601
35
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
36
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
37
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
38
tannic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable 1401-55-4
39
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
40
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
41
Panitumumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 339177-26-3 50070211
42
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
43
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
44
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
45
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
46
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 175805 71273
47
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 5311068 68602
48
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 2078-54-8 4943
49
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3

Interventional clinical trials:

(show top 50) (show all 5802)
# Name Status NCT ID Phase Drugs
1 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
2 Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Unknown status NCT01959061 Phase 4 Raltitrexed;Oxaliplatin;lipiodol
3 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
4 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
5 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
6 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
7 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
8 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
9 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
10 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
11 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
12 Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Unknown status NCT02575378 Phase 4 Metronimic chemotherapy plus Chinese Traditional Medicine;Metronimic chemotherapy
13 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
14 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
15 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
16 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
17 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
18 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
19 Intravenous Iron for Correction of Anaemia After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
20 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
21 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
22 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
23 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
24 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
25 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
26 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
27 A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer Terminated NCT00114946 Phase 4 Avastin
28 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
29 Dissemination of Colorectal Cancer Screening to Primary Care Physicians Completed NCT00441311 Phase 4
30 Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population Completed NCT01557101 Phase 4
31 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Not yet recruiting NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
32 Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC). Recruiting NCT03564938 Phase 4 Regorafenib (Stivarga, BAY73-4506)
33 Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles Completed NCT00868816 Phase 4 12 cycles of oxaliplatine based adjuvant chemotherapy;8 cycles of oxaliplatine based adjuvant chemotherapy
34 Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery Recruiting NCT03700411 Phase 4 Morphine;Piritramid;Epidural
35 Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis? Terminated NCT01740947 Phase 4 Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
36 Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery Recruiting NCT03700541 Phase 4 Morphine;Piritramid
37 Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer Completed NCT00928928 Phase 4
38 A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4 Capecitabine
39 Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
40 Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 Terminated NCT01468623 Phase 4
41 Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer Completed NCT00869271 Phase 4
42 A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer Completed NCT01695772 Phase 4 5-FU based doublet chemotherapy;bevacizumab
43 Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
44 Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer Recruiting NCT03645187 Phase 4 FOLFOX;Folfox and celecoxib
45 CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4 oxaliplatin
46 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed NCT01588990 Phase 4 Oxaliplatin;Capecitabine;Bevacizumab;Leucovorin;5-Fluouracil;Irinotecan
47 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
48 Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases Terminated NCT00327093 Phase 4 cetuximab;bevacizumab
49 Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer Completed NCT01493713 Phase 4
50 Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases Active, not recruiting NCT02015923 Phase 4 Chemotherapy- scheme

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Colorectal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Colorectal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Colorectal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: colonic neoplasms

Genetic Tests for Colorectal Cancer

Genetic tests related to Colorectal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Colon 30 AKT1 APC AXIN2 BUB1B CTNNB1 DCC DLC1 EP300 FGFR3 FLCN NRAS PIK3CA SRC TP53
2 Colorectal Cancer 30
3 Colon Cancer 30
4 Colorectal Cancer, Susceptibility to 30

Anatomical Context for Colorectal Cancer

MalaCards organs/tissues related to Colorectal Cancer:

42
Colon, Liver, Testes, Breast, Lung, Lymph Node, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Cancer:

20
The Colon, The Rectum

Publications for Colorectal Cancer

Articles related to Colorectal Cancer:

(show top 50) (show all 22021)
# Title Authors Year
1
Significance of SATB2 expression in colon cancer and its differential diagnosis in digestive tract adenocarcinoma and ovarian primary and metastatic carcinoma. ( 31101576 )
2019
2
Nanocomplexes of Graphene Oxide and Platinum Nanoparticles against Colorectal Cancer Colo205, HT-29, HTC-116, SW480, Liver Cancer HepG2, Human Breast Cancer MCF-7, and Adenocarcinoma LNCaP and Human Cervical Hela B Cell Lines. ( 30893818 )
2019
3
The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy. ( 30640791 )
2019
4
Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. ( 30987998 )
2019
5
Loss of PKM2 in Lgr5+ intestinal stem cells promotes colitis-associated colorectal cancer. ( 30996297 )
2019
6
A case of screening colonoscopy using linked-color imaging to detect ulcerative colitis-associated colorectal cancer. ( 31000480 )
2019
7
Loss of RUNX3 Immunoreactivity in Non-Neoplastic Rectal Mucosa May Predict the Occurrence of Ulcerative Colitis-Associated Colorectal Cancer. ( 30763934 )
2019
8
Increased Genetic Instability and Accelerated Progression of Colitis-Associated Colorectal Cancer through Intestinal Epithelium-specific Deletion of Klf4. ( 30108164 )
2019
9
Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer. ( 31107745 )
2019
10
Somatic mutational signatures in polyposis and colorectal cancer. ( 31108140 )
2019
11
Chemopreventive Potential of Apple Pulp Callus Against Colorectal Cancer Cell Proliferation and Tumorigenesis. ( 31058564 )
2019
12
The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells. ( 31059051 )
2019
13
Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR‑384/pleiotrophin axis. ( 31059061 )
2019
14
Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. ( 31059199 )
2019
15
A case of an elderly patient with high-grade colorectal cancer in poor general condition who showed near complete response to chemotherapy and achieved long-term survival. ( 31060020 )
2019
16
Quantitative Proteomics Identifies DNA Repair as a Novel Biological Function for Hepatocyte Nuclear Factor 4α in Colorectal Cancer Cells. ( 31060309 )
2019
17
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. ( 31060539 )
2019
18
"Liquid Biopsy" - Is it a Feasible Option in Colorectal Cancer? ( 31060647 )
2019
19
Perioperative Anemia and Transfusion in Colorectal Cancer Patients. ( 31060656 )
2019
20
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. ( 31060856 )
2019
21
Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer. ( 31060867 )
2019
22
Corrigendum to "Hypoxia-induced microRNA-590-5p promotes colorectal cancer progression by modulating matrix metalloproteinase activity" [Cancer Lett. 416 (2018) 31-41]. ( 31060874 )
2019
23
Moving miRNAs to therapeutic targets in colorectal cancer. ( 31060899 )
2019
24
Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis. ( 31069997 )
2019
25
Highly stable near-infrared dye conjugated cerasomes for fluorescence imaging-guided synergistic chemo-photothermal therapy of colorectal cancer. ( 31070203 )
2019
26
Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. ( 31070306 )
2019
27
Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. ( 31070668 )
2019
28
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. ( 31070691 )
2019
29
Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker? ( 31070713 )
2019
30
Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC). ( 31070915 )
2019
31
Improvement of Care in Patients With Colorectal Cancer: Influence of the Introduction of Standardized Structured Reporting for Pathology. ( 31070983 )
2019
32
Efficacy of preoperative colonoscopic tattooing with indocyanine green on lymph node harvest and factors associated with inadequate lymph node harvest in colorectal cancer. ( 31071272 )
2019
33
Squalene Epoxidase Inversely Correlates E-Cadherin Expression and Prolongs Overall Survival in Colorectal Cancer Patients: The Impact on Prognosis and Correlation to Clinicopathologic Features. ( 31072053 )
2019
34
Colorectal cancer screening in newly insured Medicaid members: a review of concurrent federal and state policies. ( 31072316 )
2019
35
Prognostic relevance of topoisomerase II α and minichromosome maintenance protein 6 expression in colorectal cancer. ( 31072339 )
2019
36
Anti-Colorectal Cancer Effect via Application of Polyethylene Glycol Modified Liposomal Apatinib. ( 31072433 )
2019
37
Post-colonoscopy colorectal cancer in Belgium: characteristics and influencing factors. ( 31073539 )
2019
38
Association of the prognostic nutritional index and overall survival in patients with colorectal cancer: A STROBE compliant retrospective cohort study. ( 31069966 )
2019
39
GATA1 promotes colorectal cancer cell proliferation, migration and invasion via activating AKT signaling pathway. ( 31069596 )
2019
40
TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. ( 31069156 )
2019
41
Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening. ( 31074811 )
2019
42
Letter: improving detection of colorectal cancer using two-stage investigation process-faecal immunochemical test and urinary volatile organic compounds. ( 31074900 )
2019
43
Induction of let-7e gene expression attenuates oncogenic phenotype in HCT-116 colorectal cancer cells through targeting of DCLK1 regulation. ( 31075231 )
2019
44
Cannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer. ( 31075907 )
2019
45
Is it time to change follow-up recommendations in colorectal cancer? ( 31077087 )
2019
46
Correction to: A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer. ( 31077174 )
2019
47
Is a fusobacterium nucleatum infection in the colon a risk factor for colorectal cancer?: a systematic review and meta-analysis protocol. ( 31077259 )
2019
48
Expression of Lymphocyte-Activation Gene 3 (LAG-3) Immune Checkpoint Receptor Identifies a Tumor-Reactive T Cell Population in the Peripheral Blood of Patients with Colorectal Cancer. ( 31077581 )
2019
49
Cervical and colorectal cancer screening prevalence before and after Affordable Care Act Medicaid expansion. ( 31077723 )
2019
50
Intrinsic β-catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer. ( 31078045 )
2019